Fresenius Medical Care Q3 2024 Adj EPS €0.73 May Not Be Comparable To €0.35 Estimate, Sales €4.76B Miss €4.89B Estimate
Fresenius Medical Care Q3 2024 Adj EPS €0.73 May Not Be Comparable To €0.35 Estimate, Sales €4.76B Miss €4.89B Estimate
費森尤斯醫療2024年第三季度調整後每股收益爲€0.73,可能無法與€0.35的預估相比,銷售額爲€47.6億,低於€48.9億的預估。
Fresenius Medical Care (NYSE:FMS) reported quarterly earnings of $0.73 per share which beat the analyst consensus estimate of $0.35 by 108.57 percent. This is a 28.07 percent increase over earnings of $0.57 per share from the same period last year. The company reported quarterly sales of $4.76 billion which missed the analyst consensus estimate of $4.89 billion by 2.67 percent. This is a 3.57 percent decrease over sales of $4.94 billion the same period last year.
費森尤斯醫療(紐交所:FMS)報告每股0.73美元的季度收益,超過了分析師共識預期的0.35美元,增長108.57%。這是相比去年同期每股0.57美元的收益增加了28.07%。公司季度銷售額爲47.6億美元,低於分析師共識預期的48.9億美元,下降2.67%。與去年同期49.4億美元的銷售額相比下降了3.57%。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。